Trial Profile

Randomized Open Pilot Study to Evaluate the Efficacy of Subcutaneous Sarilumab in Patients With Moderate-severe COVID-19 Infection

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 25 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sarilumab (Primary)
Indications COVID 2019 infections; COVID-19 pneumonia; Severe acute respiratory syndrome
Focus Proof of concept; Therapeutic Use
Acronyms SARCOVID

09 Nov 2021 Primary endpoint (Median (IQR) change in clinical status assessment using the 7-point ordinal scale at day 7 after randomisation) has not been met as per results presented at the ACR Convergence 2021
09 Nov 2021 Primary endpoint (Death) has not been met as per results presented at the ACR Convergence 2021
09 Nov 2021 Primary endpoint (Duration of hospitalisation (days)) has not been met as per results presented at the ACR Convergence 2021

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com